LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023

Cited by 83 works. doi:10.1016/j.annonc.2023.10.062 Open-access PDF

Authors

References